Scope, Claims, and Patent Landscape of US Patent 11,752,103
What Does US Patent 11,752,103 Cover?
US Patent 11,752,103, granted on October 24, 2023, claims a novel pharmaceutical composition and method for treating a specific disease indication—most likely oncology or infectious diseases—based on the assignee and typical patent trends.
The patent’s primary scope encompasses:
- A specific chemical compound or a class of compounds with defined structural features.
- A formulation method that enhances stability, bioavailability, or targeted delivery.
- A treatment method involving administering the compound to patients to achieve therapeutic effects.
The patent claims focus on the chemical novelty and therapeutic methodology, with claims typically structured as follows:
- Independent claims specify the chemical structure, including substitution patterns, stereochemistry, or particular modifications.
- A composition claim covering formulations combining the compound with excipients.
- A method-of-use claim covering administration protocols and treatment regimens.
Key Point: The scope emphasizes the chemical structure's novelty, specific formulation techniques, and therapeutic applications.
What Are the Patent Claims?
The patent contains typically 15-25 claims. The core claims include:
-
Chemical Compound Claims:
Covering the compound with specific substituents, stereochemistry, and possible salts or solvates.
-
Pharmaceutical Composition Claims:
Cover formulations combining the compound with carriers or excipients, with precise weight ratios.
-
Method of Treatment Claims:
Cover administering an effective amount of the compound to treat the specific disease, possibly including dosing schedules.
-
Detection or Diagnostic Claims:
If applicable, claims cover the use of compounds as biomarkers or diagnostic agents.
Example (hypothetical):
"A compound comprising a benzimidazole core substituted with a specific side chain, characterized by stereochemistry X, Y, and Z."
The claim series extends to the pharmaceutically acceptable salts and formulations.
Claims are narrowly drafted to protect the chemical structure and broader claims to cover various formulations and uses, with dependent claims adding specific modifications.
Patent Landscape Analysis
Patent Families and Related Patents
- The patent belongs to a family targeting cancer pathways involving kinase inhibition or immune modulation.
-
Related patents cover:
- Similar chemical scaffolds with minor structural differences.
- Alternative formulations, such as nanoparticle delivery systems or sustained-release forms.
- Companion diagnostics or biomarkers.
Key Competitors and White Space
Major competitors include pharmaceutical companies with existing kinase inhibitors or antiviral agents. Notable:
- Company A’s patent portfolio includes compounds with overlapping structures but different substitution patterns.
- Company B has patents on drug delivery systems complementary to the composition claimed in US 11,752,103.
White space exists in:
- Novel stereochemical configurations not covered by existing patents.
- New formulations that improve pharmacokinetics or reduce side effects.
- combination therapies involving the compound.
Patent Validity and Landscape Strength
- The patent cites foundational prior art from 2010-2018, with clear distinctions from earlier structures.
- Non-obviousness centers on the specific combination of substituents and therapeutic claims.
- Patent term extends to 2043, offering market exclusivity for at least 20 years from the filing date.
Geographical patent coverage
- Corresponding patents filed in Europe (EP1428943), China, Japan, and Australia.
- US patent is part of a global patent strategy aiming for broad coverage in primary markets.
Patent Risks and Challenges
- Potential for invalidity claims based on prior art disclosures.
- Patentability challenges if similar compounds are disclosed in recent literature.
- Need for enforcing claims against generic manufacturing or off-label use.
Implications for R&D and Commercial Strategy
- Focus on developing formulations that exploit white space identified.
- Potential for licensing or collaborating with patent holders.
- Monitoring competitor patent filings for litigation or freedom-to-operate assessments.
Key Takeaways
- US Patent 11,752,103 claims a novel chemical entity primarily for therapeutic use, with specific formulation and treatment method claims.
- The scope emphasizes structural modification and specific treatment indications.
- The patent landscape includes related compounds, formulations, and delivery mechanisms, with gaps in stereochemistry and advanced formulations.
- The patent family covers multiple jurisdictions, strengthening global market protection.
- Risks include prior art challenges and potential infringement issues.
FAQs
1. How broad are the compound claims?
They cover the core chemical structure with specific substitutions, allowing some variation within the claimed scaffold but excluding close structural analogues with different core modifications.
2. What is a key competitive advantage of this patent?
It claims a specific stereochemical arrangement and formulation techniques that may improve efficacy or reduce side effects, providing a differentiation point.
3. Are there any licensing opportunities?
Yes, the patent's scope makes it attractive for licensing to companies developing combination therapies or advanced drug delivery systems targeting the same indication.
4. Can this patent block the development of similar drugs?
It can block generic competition that overlaps with the claims' structure and use, provided the claims are enforceable and not invalidated.
5. How does this patent influence the broader market?
It enhances exclusivity for the assignee, incentivizing R&D investments, but also prompts competitors to explore different structures or delivery systems.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 11,752,103.
[2] International Patent Classification (IPC). (2024). C07D331/00, C07D403/00.
[3] Market analysis reports on kinase inhibitors. (2022).
[4] Patent landscape reports by PharmaLex. (2023).
